{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-004202","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.721938+00:00","generated_at":"2026-06-19T18:14:14.770770+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Anebulo reports Q2 fiscal 2023 net loss of $3.8M; Phase 2 trial completed for ANEB-001","bullets":["Net loss of $3.8M ($0.15 per share) vs $1.1M ($0.05) in Q2 fiscal 2022.","Cash and cash equivalents of $16.4M as of Dec 31, 2022.","Completed dosing Phase 2 trial for ANEB-001; preliminary data shows 10mg dose reduces key ACI symptoms.","Final Phase 2 data expected by end Q1 2023; End-of-Phase 2A meeting with FDA expected Q2 2023.","Continued development of parenteral formulation of ANEB-001."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-004202","json":"https://secwatch.observer/filing/0001493152-23-004202.json","markdown":"https://secwatch.observer/filing/0001493152-23-004202.md","text":"https://secwatch.observer/filing/0001493152-23-004202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/0001493152-23-004202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T18:14:14.770770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"779df7828a617fa31c09323efcbc2a224e4be3b2","claim":"Anebulo Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: net income ($3.8 million), EPS $(0.15).","evidence_excerpt":"Net loss in the second quarter of fiscal 2023 was $3.8 million, or $(0.15) per share, compared with a net loss of $1.1 million, or $(0.05) per share, in the second quarter of fiscal 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223004202/0001493152-23-004202-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2022"},{"label":"Net income","value":"($3.8 million)"},{"label":"EPS","value":"$(0.15)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}